Mary Campbell
Executive Medical Director, Global Development Lead Pfizer
Seminars
Wednesday 5th November 2025
Showcasing Clinical Performance of Vedotin ADCs, Sigvotatug Vedotin & PDLIV, in Combination With Pembrolizumab in First-Line for Thoracic Cancers
8:00 am
- Exploring clinical data from Sigvotatug vedotin and PDLIV programs in combination with pembrolizumab, highlighting the significance of vedotin ADCs causing immunogenic cell death
- Delving into the rationale and synergistic benefit of pembrolizumab combination approach in thoracic cancers
- Laying out potential for Sigvotatug vedotin and PDLIV combinations to improve outcomes for patients with thoracic cancers
